이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Xvivo Perfusion 관리

관리 기준 확인 3/4

Xvivo Perfusion's CEO는 Christoffer Rosenblad, Jan2022 에 임명되었습니다 의 임기는 2.42 년입니다. 는 SEK 23.89M 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 23.89M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 3.7 년입니다.

주요 정보

Christoffer Rosenblad

최고 경영자

SEK 5.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	2.5yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Calculating The Intrinsic Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Apr 09

Should You Think About Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Now?

Mar 19

CEO

Christoffer Rosenblad (49 yo)

2.5yrs

테뉴어

SEK 5,031,000

보상

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christoffer Rosenblad	Chief Executive Officer	2.5yrs	SEK 5.03m	0.18% SEK 22.4m
Kristoffer Nordstrom	CFO & Investor Relation	3.7yrs	데이터 없음	0.0085% SEK 1.1m
Lena Hagman	Chief Operating Officer	1.6yrs	데이터 없음	0.0063% SEK 804.1k
Ylva Vihoj	Global Human Resources Director	1.5yrs	데이터 없음	데이터 없음
Magnus Nilsson	Senior Advisor	4.1yrs	SEK 1.62m	데이터 없음
Andreas Wallinder	Chief Medical Officer	3.8yrs	데이터 없음	0.011% SEK 1.4m
Johan Holmstrom	Chief Commercial Officer	3.8yrs	데이터 없음	0.012% SEK 1.5m

3.7yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: XVIVO 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gosta Johannesson	Chairman of the Board	11.5yrs	SEK 440.00k	0.015% SEK 1.9m
Lars Henriksson	Independent Director	3.8yrs	데이터 없음	0.0076% SEK 964.9k
Erik Stromqvist	Independent Director	1.3yrs	데이터 없음	0.18% SEK 22.4m
Camilla Oberg	Independent Director	8.2yrs	SEK 130.00k	0.0034% SEK 433.1k
Lena Hoglund	Independent Director	3.8yrs	데이터 없음	0.0041% SEK 523.0k
Goran Dellgren	Independent Director	2.3yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: XVIVO 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Xvivo Perfusion 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director recently bought kr222k worth of stock

Chairman of the Board recently bought kr281k worth of stock

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Independent Director recently bought kr107k worth of stock

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Recent updates

Consensus EPS estimates increase by 10%

Now 20% undervalued

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%

Xvivo Perfusion AB (Publ) Presents Positive Results from the Australian & New Zealand Heart Preservation Study

Consensus EPS estimates increase by 14%

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Chairman of the Board recently bought kr201k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces CEO Changes

XVIVO Perfusion AB Receives Breakthrough Device Designation Grant from the FDA for the Liver Assist Device

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Xvivo Perfusion AB (publ) (OM:XVIVO) signed an agreement to acquire Machine and perfusion business from Avionord Srl for €12 million.

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

President & CEO exercised options to buy kr1.3m worth of stock.

Consensus forecasts updated